

Date: August 14, 2026

Ref. No.: KDL/SE/029/2026-27

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
---	---

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation.

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose
Company Secretary and Compliance Officer
Encl: As above



Q1 FY2026-27 Result Presentation

One of INDIA'S LARGEST Integrated
Diagnostic Service Provider



Disclaimer

This presentation contains statements that are “forward-looking statements”, including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances.

191

CT/ MRI Centres

8,400+

Patient Touch Points

221 Mn+

Tests in
in 5 Years

76

Million+

Patients Served
In Last 5 Years

64%

YoY Retail Revenue
Growth

212

Pathology Labs

19

States/UT

Presence in India

333

Districts

Presence
PAN India

75%

Centers Cover Rural
Areas of India



Krsnaa Diagnostics is one of the **fastest growing and the largest Integrated diagnostic service provider** which includes radiology, pathology and tele-radiology



Provides **quality care, accessibility, and accuracy** at **affordable rates** across various segments with a focus on the Public-Private Partnership model



One of India's largest NABH-accredited tele-radiology reporting hubs with inherent capability & capacity to process X-rays, CT scans, and MRI scans, serving patients at the remotest locations in real-time.



The workforce comprises **350+ radiologists, 100+ pathologists, and 3,000+ qualified professionals**, including clinicians, technicians and operators

Q1 FY27 Financial Performance



Particulars	Q1 FY27	Q1 FY26	Growth
Revenue	2,355	1,930	22%
EBIDTA	588	524	12%
EBIDTA Margin	25%	27%	(221 bps)
PAT	166	205	(19%)
PAT Margin	7%	11%	(360 bps)

Particulars	Q1 FY27	Q1 FY26	Growth
No. of Test Performed (Mn)	16.1	15.8	2%
No. of Patient Served (Mn)	5.1	5.0	2%
NABL Accreditation (Pathology lab)	54	54	-
NABH Accreditation (Radiology Centre)	66	31	113%

The moderation in margins is primarily a function of the upfront fixed cost base of Rajasthan laboratories, equipment, manpower and logistics being carried ahead of full utilisation.

- Note: 1. Financial results of the Company are best monitored on an annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter
 2. EBIDTA is excluding CSR & ESOP
 3. INR in mn except EPS, NABL & NABH

Retail Business Summary



Q1 FY27 – Network Update

THE SCALE-UP From a network of centres to a broader and scaled, diagnostic platform across Radiology and Pathology, built for sustained accessibility.

RADIOLOGY

Resilient scale. Larger ambition.

The platform continues to expand despite the Tamil Nadu MRI discontinuation.

CURRENT Q1 FY27 RADIOLOGY FOOTPRINT

Modality	Count Q1FY27	Increase From Q1FY26
CT	149	+4
MRI	42	+2
TELE- RADIOLOGY	1,516	+15

200+

CT / MRI

ON ORDER-BOOK COMPLETION

ONE OF ASIA'S LARGEST RADIOLOGY PLAYERS

PATHOLOGY

Depth meets last-mile reach.

Rajasthan and strategic alliances have accelerated the platform.

37 ↑ Up by **6X**
REFERENCE LABS

6 in Q1 FY26

175 ↑ Up **+54%**
SATELLITE LABS

114 in Q1 FY26

8,400+ ↑ Up **+143%**
PATIENT TOUCH POINTS

3,479 in Q1 FY26

**INDIA'S DEEPLY ROOTED
AND WIDELY ACCESSIBLE PATHOLOGY PLATFORM**

The count of radiology and pathology services continues to grow.

Driving Excellence Through Quality



**American College
of Radiology™**

India's 1st ACR Accredited
Company



India's 1st CAP Accredited Lab
at Government Facility



India's 1st NABH Accredited
Tele-Radiology Hub

Service Excellence **Pioneers of Indian Diagnostic Industry**

Driving Excellence Through Quality

ACCREDITATION LEADER

120

TOTAL ACCREDITATIONS

2.3 × Next Peer

66



NABH

accredited centers

54



NABL

accredited labs

Largest combined accreditation footprint
among tracked peers

ACCREDITATION FOOTPRINT

Krsnaa leads the peer set by a wide margin


Total NABL + NABH accreditation count




Krsnaa combines the largest NABL-accredited lab base with the largest NABH-accredited centre base in the tracked peer set.

Presence - PAN India

Well Diversified Regional Revenue Mix



■ West ■ South ■ North ■ East



India map for representation only, not to scale

Competitive Advantages

THE GROWTH STORY

Reach → Capacity → Trust → Cash Conversion

NEXT PHASE: CASH GROWTH

01 FOUNDATION

A scaled platform
already in place.

2 Cr+
Patient

30K
Doctors

24×7 · 365 DAYS

Round-the-clock availability
supports convenience and access.

8,400+ TOUCH POINTS

02 SCALE - THE ADVANTAGE

Turn network strength
into consumer growth.

212 → 290+
Labs

191 → 200+
CT / MRI Centres

1,500+
X-ray Centres

NETWORK × SCALE × PATIENT TRUST
INCREASING OPPORTUNITY FOR SUSTAINABLE GROWTH

03 WAY FORWARD

Building a larger and
more sustainable cash
business.

CASH
GROWTH
ENGINE

Assurance • Accessible • Affordable

“Bharat Ka Bharosemand Diagnostics”

Growth Drivers

POLICY TAILWINDS

3.3% → 5%

Healthcare GDP
(by 2030)

\$1,522 Bn

Est. Indian Healthcare Industry Size
in FY29-30

₹1,017 Bn

MoHFW Budget
(Union Budget 2025-26)

₹42 Bn

PM-ABHIM
(FY 2025-26)

*Sources: CareEdge Ratings report (April 2025); Rubix Industry Insights-
HEALTHCARE SERVICES; MoHFW Budget (Union Budget 2025-26);
PM-ABHIM (FY 2025-26)*



Long Tenure

*Predictable & Long-term
Business outlook:*

- Radiology avg tenure term ~10+ years
- Pathology avg tenure term ~5+ years



Captive Consumer

*Government OPD & IPD patients
attributed to:*

- District Hospitals
- Subdistrict Hospitals
- Community Healthcare centres
- Primary Healthcare Centres, etc.



Cost Leadership

Cost Optimisation:

- Volume-driven economies of scale
- Building Efficiency



Skilled Human Resource

- 350+ qualified doctors
- 3,000+ skilled technicians
- 1,000+ professionals



Robust IT Infrastructure

*Advanced Fully Integrated IT
system:*

- In-house PACS & LIMS
- Synchronizing AI
- Multiple and multi-level automation



Operational Excellence

- Pathology: Common processing units for PPP and retail both
- Radiology: Common imaging centres for PPP and retail both

Our Pricing - “Everyone Can Afford”

Segment	Test	Competition 1	Competition 2	Competition 3	Krsnaa	% lower from competitors
Radiology	CT Brain	4,500	4,500	3,500	880	(75)%
Radiology	MRI Brain	8,000	8,250	7,000	1,340	(81)%
Pathology	CBC	250	250	200	37	(82)%
Pathology	Blood Sugar	85	80	70	20	(71)%
Pathology	Thyroid	500	550	550	55	(90)%
Pathology	Vitamin D	1,500	1,250	1,450	153	(89)%
Pathology	Vitamin B12	1,000	1,100	1,300	69	(95)%
Pathology	HbA1C	550	440	400	49	(88)%

By offering services at **over 70% below** market rates, Krsnaa Diagnostics is expanding access to millions across India — and still delivering industry alike EBITDA and PAT, proving that **scale, efficiency, and impact can go hand in hand.**

Note:

Amounts are in INR.

Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information

Retail Key Strength

Forward Growth Horizon: Scale | Awareness | Technology



Pillar A: Scale & Modality Advantage

PPP-Based Ecosystem

● PPP Infrastructure Leverage

Existing CT/MRI/pathology labs deployed for PPP serve as the cost-base for retail — marginal revenue with minimal incremental fixed cost, delivering superior ROCE.

● Asset-Light Franchise Model

Partnerships with local operators, franchise models, and collection-centre networks enabling rapid expansion without heavy capital outlays.

● Hub-and-Spoke Architecture

Centralized reference labs processing samples from a satellite network ensure quality consistency and cost efficiency at scale.

● Home Collection Scale-Up

Expanding phlebotomist network; digital platform enables seamless booking, real-time sample tracking, and fast report delivery.

● 24/7 Accessibility

RPL brand positioned on availability, affordability, and reliability — differentiated from hospital-based and premium competitors.



Pillar B: Awareness

Aggregator & Platform Partnerships

● RPL on Health Platforms

Positioning RPL services on health-tech aggregators and insurance platforms — scalable B2B2C patient acquisition at low CAC

● Corporate Wellness

Integration into employee wellness programs with corporates and insurers — predictable recurring volume

● Home Collection App

Mobile-first booking with real-time tracking — frictionless diagnostic experience for urban and semi-urban consumers

● Preventive Health Packages

Customised wellness screening bundles targeting early detection — India's growing ₹2.98 Tr diagnostic TAM by FY30

● 30,000+ Doctor Network

Digital referral platform strengthening doctor engagement across 5 states for a sustained B2C funnel



Pillar C: AI-Enabled Diagnostics

Technology as a Scale Multiplier

● AI-Powered Radiology

Automated image analysis & AI-assisted CT/MRI reporting — improves throughput, reduces radiologist dependency

● Digital Pathology

AI-enabled interpretation for scalable, consistent results — virtual expert consultation across geographies

● Teleradiology Platform

Remote specialist reporting for PPP contracts in rural & under-served regions

● LIMS & Operations

Real-time tracking, quality control, and TAT optimisation across the hub-and-spoke network

● ACR & CAP Accreditation

First company in India to receive American College of Radiology accreditation — unmatched radiology credential along with CAP in pathology

Retail-Forward Growth Journey

Six engines powering a retail-led growth platform

EXPAND • DEEPEN • PREVENT • PENETRATE • COLLECT • CONVERT



RETAIL IS THE GROWTH PLATFORM

A six-engine model combining footprint expansion, network depth, preventive care, radiology, home collection, and digital conversion.



Patient Experience at Its Best

Growth Engine- Enabling Reliable Diagnostics



Amravati, Maharashtra



Nanded, Maharashtra

Actual centre images

Growth Engine- Rajasthan Pathology



Kishanpole, Mother Lab



Nagaur, Mother Lab

Actual centre images

Activities in Retail Business

Doctor Engagement Activities



Activities in Retail Business

Health Checkup Camp/Awareness Programs



Activities in Retail Business

Medical Conferences



Activities in Retail Business

Center Branding





Financial Performance

Consolidated Financial Performance

In INR Mn

Particulars	Q1 FY 27		Q1 FY 26		Q4 FY 26	
	Amount	%	Amount	%	Amount	%
Revenue from operations	2,355		1,930		1,926	
Expenses						
Cost of Material Consumed	502	21%	474	25%	444	23%
Employee benefits expense	357	15%	350	18%	327	17%
Fees to hospitals and others	406	17%	154	8%	143	7%
Other expenses	502	21%	428	22%	453	24%
Total Expenses	1,767	75%	1,406	73%	1367	71%
EBITDA Before CSR & ESOP	588	25%	524	27%	559	29%
CSR and ESOP	8	0.3%	10	1%	10	1%
EBITDA	580	25%	514	27%	549	29%
Less: Finance costs	148	6%	63	3%	121	6%
Less: Depreciation	280	12%	216	11%	226	12%
Add: Other income	72	3%	40	2%	314	16%
PBT	224	10%	275	14%	516	27%
Tax	59	2%	69	4%	100	5%
PAT	166	7%	205	11%	416	22%

The moderation in margins is primarily a function of the upfront fixed cost base of Rajasthan laboratories, equipment, manpower and logistics being carried ahead of full utilisation.

Contact Information

This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future / likely events or circumstances.

For further information please contact

Krsnaa Diagnostics

Sujoy Bose, Head- Secretarial, Legal and Compliance

investors@krsnaa.in

Contact: +91 73910 40109



For further information please contact

Krsnaa Diagnostics

Sujoy Bose, Head- Secretarial, Legal and Compliance



investors@krsnaa.in



[Contact: +91 73910 40109](tel:+917391040109)



<https://krsnaadiagnostics.com>